AptivusTreatment for HIV Infection
Boehringer Ingelheim Submits New Drug Application to U.S. Food and Drug Administration for Tipranavir
Priority Review Requested for Investigational Anti-HIV Agent
RIDGEFIELD, Conn., October 25, 2004 -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tipranavir. The Company is seeking accelerated approval of tipranavir and has requested a priority, six-month review of the NDA. Priority review designation is based upon whether a drug provides a significant improvement in the treatment of a serious or life-threatening disease. Tipranavir is a non-peptidic protease inhibitor under investigation for the treatment of HIV-1 infection in combination with other antiretroviral agents.
"Boehringer Ingelheim has worked diligently to develop tipranavir as quickly as possible in response to the urgent need for new therapies for treatment-experienced HIV-positive patients," said Paul Fonteyne, Executive Vice President and Head of Sales & Marketing at Boehringer Ingelheim Pharmaceuticals, Inc.
Two large-scale Phase 3 clinical trials, RESIST-1 and RESIST-2,1 form the foundation of the NDA for tipranavir. These studies are randomized, controlled, open-label trials designed to examine the safety and efficacy of tipranavir, boosted with low-dose ritonavir (tipranavir/r), versus a low-dose ritonavir-boosted comparator protease inhibitor in treatment-experienced patients. Interim data from RESIST-1 will be presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington, DC on October 31.
"The number of treatment-experienced HIV-infected patients in the U.S. continues to grow," said Dr. Kathleen Squires, Associate Professor of Medicine at the Keck School of Medicine at the University of Southern California and Medical Director at the Rand Schrader Clinic of the LAC + USC Medical Center. "Tipranavir may offer an important option for those who need new therapy to stay ahead of HIV drug resistance."
Tipranavir is a non-peptidic protease inhibitor currently in late Phase 3 clinical development -- the final stage of testing prior to the submission of data to the FDA for review for marketing approval. Tipranavir is also being evaluated for use in pediatric and treatment-naïve patient populations in Phase 2 and 3 studies that are currently underway.
The investigational drug, tipranavir, does not cure HIV infection/AIDS or prevent transmission of HIV to others.
Boehringer Ingelheim is committed to the research and development of novel antiretroviral agents. Viramune (nevirapine), a product of original research done at Boehringer Ingelheim, was the first member of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of anti-HIV drugs. Boehringer Ingelheim is involved in basic research and is committed to the development of tipranavir and improving HIV therapy by providing physicians and patients with innovative antiretrovirals.
For more information on Boehringer Ingelheim Pharmaceuticals, Inc., please visit us.boehringer-ingelheim.com.
1 The RESIST (Randomized Evaluation of Strategic Intervention in Multi- Drug ReSistant Patients with Tipranavir) clinical trial program is one of the largest study programs undertaken with an investigational antiretroviral agent in patients previously treated with multiple combinations of antiretroviral drug regimens.
Posted: October 2004
- New Aptivus (tipranavir) Oral Solution Approved forTreatment-Experienced Pediatric and Adolescent HIV Patients - June 24, 2008
- Aptivus (tipranavir) Capsules Granted Full Approval by the U.S. FDA - October 5, 2007
- FDA Approves Aptivus for HIV Infection - June 22, 2005
- FDA Antiviral Drugs Advisory Committee Recommends Accelerated Approval for Investigational Anti-HIV Drug Tipranavir - May 19, 2005